Changing therapeutic landscape--the last decade.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Immunotherapy has become a primary treatment modality in lymphoma over the past decade.
• Rituximab significantly improves survival in patients with CD20-positive lymphomas.
• Other therapeutic approaches like radioimmunotherapy and conventional radiotherapy are declining in prominence.

Purpose of the Study:

• To review the significant advancements in lymphoma treatment over the last decade.
• To assess the impact of immunotherapy, chemotherapy, and targeted drugs on lymphoma patient outcomes.
• To identify unresolved challenges and future directions in lymphoma therapy.

Main Methods:

• Review of recent clinical trials and therapeutic developments in lymphoma.
• Analysis of the efficacy of immunotherapy, including monoclonal antibodies (MoAbs).
• Evaluation of chemotherapy regimens, radioimmunotherapy, and targeted drug therapies.

Main Results:

• Rituximab addition enhances survival across most CD20+ lymphoma patient groups.
• Bendamustine shows promise as an effective cytotoxic agent for indolent lymphomas.
• Treatment for Hodgkin lymphoma (HL) is increasingly personalized based on prognostic factors.

Conclusions:

• Immunotherapy, especially rituximab, represents a major breakthrough in lymphoma care.
• The long-term impact of novel targeted drugs and MoAbs requires further investigation.
• Advances in lymphoma biology understanding are crucial for addressing T-cell lymphomas and high-risk DLBCL.